Skip to Main Content

Paper Details

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen ÿ CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
Journal of Clinical Oncology
38
2022
ABBV, ABBV-383, B-, B-Cell Maturation Antigen, CD3, Human, Patients, RRMM, Relapsed/Refractory Multiple Myeloma, VGPR, anemia, anti-CD38 monoclonal antibody, cytokine, cytokine release syndrome, fatigue, human, neutropenia, patients, relapsed/refractory multiple myeloma
Author NameAffiliation
Ravi VijWashington University School of Medicine
  • 1 - 1

Datasets

Release 1.2